Streamlining Gastroenterology Prior Authorizations with Inovalon Clearinghouse Integration

Klivira integrates seamlessly with the Inovalon Clearinghouse to deliver a robust prior authorization automation solution specifically tailored for gastroenterology practices and health systems.

For revenue cycle directors and prior authorization coordinators, managing the high-volume, complex prior authorizations in gastroenterology can be a significant administrative burden. Integrating a specialized automation platform with your existing clearinghouse, such as Inovalon, is crucial for improving efficiency, reducing turnaround times, and minimizing denials for critical GI treatments and procedures.

The Intersection: Gastroenterology PA and Clearinghouse Operations

Gastroenterology prior authorizations are characterized by specific requirements for high-cost biologics, advanced imaging, and endoscopic procedures. The Inovalon Clearinghouse, known for its data exchange and analytics capabilities, serves as a vital conduit for transmitting PA requests and receiving responses. Klivira leverages this secure channel to automate the complex, evidence-based PA workflows unique to GI.

High-Volume GI Prior Authorization Triggers

Biologics for IBD (e.g., Humira, Stelara, Skyrizi, Entyvio) and other specialty IBD drugs
Hepatitis C direct-acting antivirals (e.g., Epclusa, Mavyret)
Advanced imaging (e.g., MRCP, MR enterography, CT enterography)
Endoscopic procedures (e.g., capsule endoscopy, ERCP, EUS)
Bariatric surgery (gastric bypass, sleeve gastrectomy)

Navigating GI Documentation and Payer Policies via Inovalon

Gastroenterology PA often requires extensive documentation aligning with ACG, AGA, and AASLD guidelines. Klivira's integration with the Inovalon Clearinghouse facilitates the structured submission of this critical data, including diagnosis confirmation, disease severity scores (Mayo score, CDAI), prior conventional therapy trials, and screening results (TB, hepatitis). This ensures payer requirements are met for agents like IBD biologics, where step therapy compliance is critical.

Addressing Common GI Prior Authorization Denial Reasons

Denials in gastroenterology frequently stem from issues such as step therapy non-compliance for IBD biologics, missing disease severity documentation, or insufficient pre-biologic screening records. For Hep C DAAs, fibrosis-stage documentation gaps are common. By connecting with the Inovalon Clearinghouse, Klivira standardizes data submission, pre-validates against payer-specific rules, and flags potential denial triggers before submission, improving first-pass approval rates.

Klivira's Approach to Gastroenterology PA with Inovalon Integration

Klivira's platform is designed to address the specific workflow constraints of gastroenterology, including chronic-treatment re-authorization burdens for IBD biologics and the variability in biosimilar substitution policies. Our system, integrated with the Inovalon Clearinghouse, automates the routing of medical-vs-pharmacy benefit claims and ensures that treatment-naive vs. treatment-experienced classifications for IBD biologics and Hep C DAAs are accurately reflected in PA submissions, reducing misclassification-driven denials.

Frequently asked questions

How does Klivira integrate with the Inovalon Clearinghouse for GI prior authorizations?

Klivira integrates with the Inovalon Clearinghouse to facilitate the secure and standardized exchange of prior authorization requests and responses. This connection allows for the automated submission of necessary clinical documentation from your EMR, leveraging Inovalon's robust data channels to payers for efficient processing and status updates.

What specific gastroenterology procedures and drugs benefit most from this integration?

This integration significantly benefits high-volume, high-cost prior authorization categories in gastroenterology. This includes biologics for IBD (e.g., Humira, Stelara), Hepatitis C direct-acting antivirals, advanced imaging (e.g., MR enterography), and complex endoscopic procedures like capsule endoscopy, where extensive documentation and specific payer criteria apply.

Can this integration help with step therapy requirements for IBD biologics?

Yes, Klivira's platform incorporates ACG/AGA-guideline-aware step therapy logic. When integrated with the Inovalon Clearinghouse, it ensures that your prior authorization submissions for IBD biologics accurately reflect prior conventional therapy trials or biosimilar substitutions, helping to prevent denials based on unmet step therapy requirements.

How does Klivira manage ongoing re-authorizations for chronic GI conditions?

For chronic GI conditions like IBD requiring biologics, Klivira automates the periodic re-authorization workflow. The system tracks re-authorization deadlines, prompts for updated clinical documentation (e.g., disease response), and facilitates resubmission through the Inovalon Clearinghouse, minimizing lapses in coverage and administrative overhead.

Is the integration compliant with HIPAA and secure for PHI exchange?

Yes, Klivira's integration with the Inovalon Clearinghouse adheres to industry-standard security protocols and is designed to ensure HIPAA compliance for the exchange of PHI. Both platforms prioritize data security and patient privacy throughout the prior authorization process.